DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small cell lung cancer
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Daiichi Sankyo Inc.
- Target Recruit Count
- 37
- Registration Number
- 2023-508003-20-00
- Locations
- 🇮🇹
Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy
🇪🇸Hospital Universitario Puerta De Hierro De Majadahonda, Majadahonda, Spain
🇪🇸Hospital Universitario Hm Sanchinarro, Madrid, Spain
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT04526704
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 666
- Registration Number
- NCT04519944
- Locations
- 🇩🇪
Zentralklinik Bad Berka, Bad Berka, Germany
🇩🇪SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald, Bad Friedrichshall, Germany
🇩🇪Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 137
- Registration Number
- NCT04484142
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸UCLA, Santa Monica, California, United States
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT04479436
- Locations
- 🇺🇸
Highlands Oncology, Fayetteville, Arkansas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
- Conditions
- Hepatic ImpairmentModerate Impaired Hepatic Function
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT04473664
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 34
- Registration Number
- NCT04276415
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University of St. Louis, Saint Louis, Missouri, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 28
- Registration Number
- NCT04276662
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 16
- Registration Number
- NCT04223635
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
- Conditions
- Malignant Solid TumorAdvanced Solid Tumor
- Interventions
- Drug: Ifinatamab deruxtecan (I-DXd)
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 250
- Registration Number
- NCT04145622
- Locations
- 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵Kindai University Hospital, Osaka-Sayama, Japan
🇺🇸Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States